Bio-Techne Corp (TECH)

Sep 26, 2026

Bio-Techne (TECH) shareholders have approved the acquisition of the company by Merck KGaA for $73 a share, valuing the business at approximately $11.3 billion. Simultaneously, shareholders rejected the executive compensation proposal tied to the deal, signaling their disapproval of the pay arrangements. The deal is expected to close in late 2026 or early 2027, pending remaining regulatory approvals outside the U.S., with the focus now shifting from price to timing for investors.

Sep 25, 2026

Robert V Baumgartner, a Board Member at Bio-Techne (NASDAQ: TECH), exercised stock options for 15,940 shares, valued at $754,759. The transaction was disclosed in an SEC filing on September 24. Bio-Techne specializes in life sciences manufacturing, serving pharmaceutical, biotech, academic, and diagnostic markets, with its protein sciences segment being the largest revenue contributor.

Sep 23, 2026

Shareholders of Bio-Techne Corporation have approved the definitive merger agreement for Merck KGaA to acquire the company for approximately USD 11.3 billion. This all-cash deal, valued at USD 73.00 per share, represents Merck KGaA's largest acquisition since 2015 and an important strategic move under its new CEO. While the US antitrust waiting period has expired, regulatory reviews in other jurisdictions are ongoing, with closing expected in late 2026 or early 2027.

Sep 23, 2026

Bio-Techne Corporation shareholders have approved the definitive agreement for Merck KGaA, Darmstadt, Germany to acquire the company. This marks a significant step towards completing the transaction, which is expected to close by late 2026 or early 2027, pending regulatory approvals. The acquisition aims to combine complementary life sciences organizations, offering substantial cash value to Bio-Techne shareholders and positioning the combined entity to support various life science workflows.

Sep 15, 2026

Bio-Techne (TECH) has seen its stock price rebound significantly over the past three months, though it's been flat recently. The company is currently valued as 4% overvalued based on a framework that considers long-term trends in therapies and diagnostics, driven by chronic and age-related diseases. Investors are encouraged to assess the underlying metrics and risks, such as prolonged biotech funding pressure or tougher tariffs, to determine future investment opportunities.